7-Benzyl-3-chloro-1-(cyclohexylamino)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile | 327100-92-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-Benzyl-3-chloro-1-(cyclohexylamino)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile
• 英文别名: 7-benzyl-3-chloro-1-(cyclohexylamino)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile
• CAS: 327100-92-5
• 化学式: C₂₂H₂₅ClN₄
• 分子量: 380.92
• InChiKey: LZQVWYQWHQZPMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-Benzyl-3-chloro-1-(cyclohexylamino)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 7-benzyl-N5-cyclohexyl-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridine-1,5-diamine
  参考文献：
  名称：

  Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists

  摘要：

  The original structure of a high-throughput screening hit obtained from an external vendor was revised based on multiple NMR studies. The active compound was re-synthesized via a novel route and its structure and biological activity as a BRS-3 agonist were unambiguously confirmed. Multi-gram quantities of the hit were prepared for pharmacokinetic and efficacy studies. The synthetic strategy allowed for the preparation of multiple analogs for SAR exploration. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.065
• 作为产物：
  描述：

  7-benzyl-1,3-dichloro-5,6,7,8-tetrahydro-[2,7]-naphthyridine-4-carbonitrile 、 环己胺 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 7-Benzyl-3-chloro-1-(cyclohexylamino)-5,6,7,8-tetrahydro-2,7-naphthyridine-4-carbonitrile
  参考文献：
  名称：

  Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists

  摘要：

  The original structure of a high-throughput screening hit obtained from an external vendor was revised based on multiple NMR studies. The active compound was re-synthesized via a novel route and its structure and biological activity as a BRS-3 agonist were unambiguously confirmed. Multi-gram quantities of the hit were prepared for pharmacokinetic and efficacy studies. The synthetic strategy allowed for the preparation of multiple analogs for SAR exploration. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.065